Replies to post #97856 on Biotech Values

[BTH]

You can add Exelixis XL184 to that list...

(it was just recently dumped by BMY)

[gym gravity]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or later and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.

Edits: CORT

Company  Product     Phase   Indication (notes)       
  =======  =======     =====   ==================       
  ARNA     Lorcaserin  NDA     Obesity       
  ARYX     Budiodarone 2b      Atrial Fibrillation     
  ARYX     Tecarfarin  3       VTE prevention (failed initial ph-3)            
  CORT     Corlux      3       Cushing’s Syndrome 
  BPAX     Libigel     3       Female Sexual Desire Disorder  
  HNAB     Marqibo     2b      ALL (ENZN failed acc. approval in NHL)    
  JAV      Dyloject    NDA     Post-op pain (approved in UK)       
  JAV      Ketamine    3       Acute pain       
  ONCY     Reolysin    3       SCC Head & Neck cancer (ph-3 SPA) 	   
  OREX     Contrave    NDA     Obesity       
  OXGN     Zybrestat   3       Anaplastic thyroid cancer       
  MNKD     Afrezza     BLA     Diabetes (CRL rec’d 3/15/10)       
  Pharming Rhucin      apprvd  HAE (approved in Europe; US status unclear)       
  SOMX     Silenor     apprvd  Insomnia (low dose of generic doxepin)       
  SVNT     Krystexxa   BLA     Gout (response to CRL submtd 3/30/10)       
  VVUS     Qnexa       NDA     Obesity

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.